Projects per year
Fingerprint Dive into the research topics where Carlos Graux is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 22 Similar Profiles
Protein-Tyrosine Kinases
Medicine & Life Sciences
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Medicine & Life Sciences
Meta-Analysis
Medicine & Life Sciences
Blood Vessels
Medicine & Life Sciences
Leukemia
Medicine & Life Sciences
Endothelial Cells
Medicine & Life Sciences
Biomarkers
Medicine & Life Sciences
Atherosclerosis
Medicine & Life Sciences
Network
Recent external collaboration on country level. Dive into details by clicking on the dots.
Projects 2013 2016
Etude miR-126 impliqué en oncogenèse
MUYLKENS, B., Graux, C., GEORGE, F. & Finet, L.
1/12/13 → …
Project: Research
Test sanguin de détection/pronostic de cancer
POPA, C., De Ronde, T., Rahier, J., D'Hondt, L., Graux, C., GEORGE, F., Finet, L. & Herzog, M.
1/12/13 → …
Project: Research
Etude de l’effet potentiel de macrophages sur la cytotoxicité de molécules chimiothérapeutiques vis-à-vis de cellules cancéreuses
Graux, C., MICHIELS, C. & GENIN, M.
1/12/13 → 30/09/14
Project: Research
Télévie: Etude de la résistance des tumeurs aux agents utilisés en chimiothérapie : caractérisation et validation d’un gène candidat
MICHIELS, C., Graux, C., D'Hondt, L., GEORGE, F. & Finet, L.
1/12/13 → 30/09/16
Project: Research
Research Output 2012 2019
An updated meta-analysis of the risks of arterial and venous occlusive events with new generation BCR-ABL TKIs in patients with chronic myeloid leukemia
Haguet, H., Mullier, F., Graux, C., Dogne, J-M. & Douxfils, J., 13 Jun 2019.Research output: Contribution to conference › Poster
Characterization of the role of TMEM45A in cancer cell sensitivity to cisplatin
Schmit, K., Chen, J-W., Ayama-Canden, S., Fransolet, M., Finet, L., Demazy, C., D’Hondt, L., Graux, C. & Michiels, C., 2019, In : Cell Death and Disease. 10, 12, 18 p., 919.Research output: Contribution to journal › Article
Open Access
File
Cisplatin
Neoplasms
RNA Sequence Analysis
Apoptosis Regulatory Proteins
Proteins
In vitro investigations of the effect of BCR-ABL Tyrosine Kinase Inhibitors on endothelial cell viability
Haguet, H., Graux, C., Dogne, J-M., Mullier, F. & Douxfils, J., Jan 2019.Research output: Contribution to conference › Poster
BCR-ABL Tyrosine Kinase Inhibitors: Which Mechanism(s) May Explain the Risk of Thrombosis?
Haguet, H., Douxfils, J., Chatelain, C., Graux, C., Mullier, F. & Dogne, J-M., 2018, In : TH Open. 02, 1, p. e68-e88Research output: Contribution to journal › Review article
Open Access
File
Circulating MicroRNAs as Biomarkers in Diffuse Large B-cell Lymphoma: A Pilot Prospective Longitudinal Clinical Study
Bouvy, C., Wannez, A., George, F., Graux, C., Chatelain, C. & Dogné, J-M., 18 Jan 2018, In : Biomarkers in cancer. 10, p. 1179299X18781095Research output: Contribution to journal › Article
Open Access
Lymphoma, Large B-Cell, Diffuse
MicroRNAs
Longitudinal Studies
Biomarkers
Clinical Studies
Datasets
Risk of arterial and venous occlusive events in chronic myeloid leukemia patients treated with new generation BCR-ABL tyrosine kinase inhibitors: a systematic review and meta-analysis
Graux, C. (Contributor), Figshare, 29 Nov 2016
DOI: 10.6084/m9.figshare.4265168.v1, https://figshare.com/articles/Risk_of_arterial_and_venous_occlusive_events_in_chronic_myeloid_leukemia_patients_treated_with_new_generation_BCR-ABL_tyrosine_kinase_inhibitors_a_systematic_review_and_meta-analysis/4265168/1 and one more link, https://ndownloader.figshare.com/files/6948968 (show fewer)
Dataset
Activities 2015 2019
- 6 Oral presentation
Mécanismes thrombotiques des inhibiteurs de tyrosine kinase ciblant BCR-ABL
Hélène Haguet (Speaker), Jonathan Douxfils (Speaker), François Mullier (Speaker), Christian Chatelain (Speaker), Carlos Graux (Speaker), Jean-Michel Dogne (Speaker)21 Mar 2019
Activity: Talk or presentation types › Oral presentation
In vitro effects of BCR-ABL TKIs on endothelial cell survival and functions
Hélène Haguet (Speaker), Jonathan Douxfils (Speaker), Christian Chatelain (Speaker), Carlos Graux (Speaker), François Mullier (Speaker), Jean-Michel Dogne (Speaker)9 Feb 2018
Activity: Talk or presentation types › Oral presentation
Risk of vascular occlusive events with BCR-ABL TKIs in CML
Hélène Haguet (Speaker), Jonathan Douxfils (Speaker), François Mullier (Speaker), Christian Chatelain (Speaker), Carlos Graux (Speaker), Jean-Michel Dogne (Speaker)25 Feb 2017
Activity: Talk or presentation types › Oral presentation
Risk of vascular occlusive events with BCR-ABL TKIs in CML - A systematic review and meta-analysis
Hélène Haguet (Speaker), Jonathan Douxfils (Speaker), François Mullier (Speaker), Christian Chatelain (Speaker), Carlos Graux (Speaker), Jean-Michel Dogne (Speaker)28 Apr 2016
Activity: Talk or presentation types › Oral presentation
Risk of vascular occlusive events with BCR-ABL TKIs in CML - A systematic review and meta-analysis
Hélène Haguet (Speaker), Jonathan Douxfils (Speaker), François Mullier (Speaker), Christian Chatelain (Speaker), Carlos Graux (Speaker), Jean-Michel Dogne (Speaker)29 Jan 2016
Activity: Talk or presentation types › Oral presentation
Thesis
Implication de la protéine TMEM45A dans la chimiorésistance
Author: Schmit, K., 2019Supervisor: Michiels, C. (Supervisor), Poumay, Y. (President), D'Hondt, L. (Jury), Graux, C. (Jury), Noël, A. (External person) (Jury) & Gillet, J. (Jury)
Student thesis: Doc types › Doctor of Sciences
File
Roles of extracellular vesicles and their microRNA cargo in chemotherapeutic resistance, pro-coagulant phenotype and as potential biomarkers in diffuse large B-cell lymphoma
Author: Bouvy, C., 16 Oct 2017Supervisor: Dogne, J. (Supervisor), Chatelain, C. (Co-Supervisor), Caron, N. (President), Graux, C. (Jury), Michiels, C. (Jury), Stamatopoulos, B. (External person) (Jury) & Ingrid, S. (External person) (Jury)
Student thesis: Doc types › Doctor of Biomedical and Pharmaceutical Sciences
Press / Media
Volition Creates Clinical Evaluation Committee
14/11/11 → 16/11/11
2 items of Media coverage
Press/Media: Expert Comment